Literature DB >> 11683387

CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles.

T K Ko1, E Kelly, J Pines.   

Abstract

We have isolated and characterised a novel human protein kinase, Cdc2-related kinase with an arginine/serine-rich (RS) domain (CrkRS), that is most closely related to the cyclin-dependent kinase (CDK) family. CrkRS is a 1490 amino acid protein, the largest CDK-related kinase so far isolated. The protein kinase domain of CrkRS is 89% identical to the 46 kDa CHED protein kinase, but outside the kinase domains the two proteins are completely unrelated. CrkRS has extensive proline-rich regions that match the consensus for SH3 and WW domain binding sites, and an RS domain that is predominantly found in splicing factors. CrkRS is ubiquitously expressed in tissues, and maps to a single genetic locus. There are closely related protein kinases in both the Drosophila and Caenorhabditis elegans genomes. Consistent with the presence of an RS domain, anti-CrkRS antibodies stain nuclei in a speckled pattern, overlapping with spliceosome components and the hyperphosphorylated form of RNA polymerase II. Like RNA polymerase II, CrkRS is a constitutive MPM-2 antigen throughout the cell cycle. Anti-CrkRS immunoprecipitates phosphorylate the C-terminal domain of RNA polymerase II in vitro. Thus CrkRS may be a novel, conserved link between the transcription and splicing machinery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683387     DOI: 10.1242/jcs.114.14.2591

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  53 in total

1.  A protein-domain microarray identifies novel protein-protein interactions.

Authors:  Alexsandra Espejo; Jocelyn Côté; Andrzej Bednarek; Stephane Richard; Mark T Bedford
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

Review 2.  Nuclear speckles.

Authors:  David L Spector; Angus I Lamond
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

3.  A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking.

Authors:  Véronique Baldin; Muriel Militello; Yann Thomas; Christine Doucet; Weronika Fic; Stephanie Boireau; Isabelle Jariel-Encontre; Marc Piechaczyk; Edouard Bertrand; Jamal Tazi; Olivier Coux
Journal:  Mol Biol Cell       Date:  2008-02-06       Impact factor: 4.138

Review 4.  Functional evolution of cyclin-dependent kinases.

Authors:  John H Doonan; Georgios Kitsios
Journal:  Mol Biotechnol       Date:  2009-01-15       Impact factor: 2.695

5.  Phosphorylation of RNAPII: To P-TEFb or not to P-TEFb?

Authors:  Bartlomiej Bartkowiak; Arno L Greenleaf
Journal:  Transcription       Date:  2011-05

6.  Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.

Authors:  Kaiwei Liang; Xin Gao; Joshua M Gilmore; Laurence Florens; Michael P Washburn; Edwin Smith; Ali Shilatifard
Journal:  Mol Cell Biol       Date:  2015-01-05       Impact factor: 4.272

7.  CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.

Authors:  Hee-Joo Choi; Sora Jin; Hani Cho; Hee-Young Won; Hee Woon An; Ga-Young Jeong; Young-Un Park; Hyung-Yong Kim; Mi Kyung Park; Taekwon Son; Kyueng-Whan Min; Ki-Seok Jang; Young-Ha Oh; Jeong-Yeon Lee; Gu Kong
Journal:  EMBO Rep       Date:  2019-08-30       Impact factor: 8.807

Review 8.  Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.

Authors:  Arno L Greenleaf
Journal:  Transcription       Date:  2018-10-22

9.  Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.

Authors:  Hung-Hsi Chen; Yu-Chiuan Wang; Ming-Ji Fann
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

10.  Alternative splicing and tumor progression.

Authors:  Claudia Ghigna; Cristina Valacca; Giuseppe Biamonti
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.